ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Bioqual Inc (PK)

Bioqual Inc (PK) (BIOQ)

72.50
0.00
(0.00%)
Closed July 26 4:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
72.50
Bid
51.00
Ask
200.00
Volume
-
0.00 Day's Range 0.00
59.00 52 Week Range 80.00
Market Cap
Previous Close
72.50
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
379
Shares Outstanding
894,416
Dividend Yield
0.69%
PE Ratio
77.66
Earnings Per Share (EPS)
0.93
Revenue
62.66M
Net Profit
835k

About Bioqual Inc (PK)

BIOQUAL, Inc. is committed to providing quality research, model development, pre-clinical, testing/assay, and consulting services to commercial clients and Government laboratories. BIOQUAL, Inc. is committed to providing quality research, model development, pre-clinical, testing/assay, and consulting services to commercial clients and Government laboratories.

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bioqual Inc (PK) is listed in the Coml Physical, Biologcl Resh sector of the OTCMarkets with ticker BIOQ. The last closing price for Bioqual (PK) was $72.50. Over the last year, Bioqual (PK) shares have traded in a share price range of $ 59.00 to $ 80.00.

Bioqual (PK) currently has 894,416 shares outstanding. The market capitalization of Bioqual (PK) is $64.85 million. Bioqual (PK) has a price to earnings ratio (PE ratio) of 77.66.

BIOQ Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10072.572.572.516672.5CS
40072.572.572.521272.5CS
12-0.5-0.684931506849737372.537972.5CS
260.50.69444444444472807034873.49928236CS
524.496.6019702984968.01805949568.49368032CS
156-2.5-3.3333333333375108.55748978.47319093CS
26039116.41791044833.5108.52858763.85221239CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

BIOQ Discussion

View Posts
AskMuncher AskMuncher 4 years ago
$BIOQ BIOQUAL Presents Financial Results for Fiscal Year 2020 and Declares Dividend
Press Release | 09/15/2020
BIOQUAL ((OTC Pink: BIOQ) (www.bioqual.com):



2020




2019




Revenue

$

46,360,201


$

39,478,079




Income Before Income Tax

$

5,488,938


$

3,709,246




Net Income

$

4,230,938


$

2,830,875




Basic Earnings per Share








of Common Stock

$

4.74


$

3.17


Diluted Earnings per Share








of Common Stock

$

4.73


$

3.17


Weighted Average








Number of Shares Outstanding






For Basic Per Share



893,416




893,416


Weighted Average








Number of Shares Outstanding






For Diluted Earnings Per Share



893,971




893,655

BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020. This is the nineteenth dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Company’s ability to perform under its contracts in accordance with the requirements of the contracts; the actual costs incurred in performing the Company’s contracts and its ability to manage its costs, including its capital expenditures; dependence on third parties; future capital needs; the ability to fund its capital needs through the use of its cash on hand and line of credit; and the future availability and cost of financing/capital sources to the Company.


View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005969/en/
👍️0
Ubertino Ubertino 9 years ago
Get on a decent exchange!

Too easily to manipulate as an OTC-Pinky!

Get on a decent exchange - NYSE or affiliate - then I might be interested.
👍️0

Your Recent History

Delayed Upgrade Clock